The CataloniaBio & HealthTech night gathered more than 200 entrepreneurs, executives and investors from the biomedical field in the modernist enclosure of Sant Pau in Barcelona.

The jury of the Employers Awards has granted a prize to Antonio Parente recognizing his professional trajectory. The prize was awarded by Health Counsellor, Alba Vergès.

CataloniaBio & HealthTech recognized Antonio Parente, promoter of the Patronal in 2006, for his business trajectory. In 1987, Antonio Parente cofounded the Grupo Lipotec, which was sold years later in one of the biggest transactions of the, at that time, young Catalan biotech sector.

Nowadays Antonio Parente is part of the board of different companies such as GP Pharm, BCN Peptides and Speciping, and the promotor of new projects such as Sepsia Therapeutics.

Antonio Parente highlighted that this award “wouldn´t have been possible without the business group’s professional human team”.

BCN Peptides is working in a research program having as therapeutic target Lysosomal Storage diseases, a group or rare inherited metabolic disorders that result from defects in lysosomal function.

The project, enclosed in “Nuclis d’Innovació Tecnològica” program from ACCIÓ, is cofinanced with the European Union FEDER funds.

BCN Peptides supports IDP-Pharma in the development of a new chemical entity aimed to treat Multiple Myeloma.

The collaboraive project has been granted with funds from the European Union FEDER via ACCIO and its programme “Nuclis d’Innovació Tecnològica”.